Compare OABI & PSEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OABI | PSEC |
|---|---|---|
| Founded | 2012 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 773.1M | 771.4M |
| IPO Year | 2021 | 2012 |
| Metric | OABI | PSEC |
|---|---|---|
| Price | $4.66 | $1.26 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $8.33 | N/A |
| AVG Volume (30 Days) | 1.3M | ★ 8.3M |
| Earning Date | 10-30-2026 | 11-04-2026 |
| Dividend Yield | N/A | ★ 33.33% |
| EPS Growth | 6.56 | ★ 104.44 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $18,666,000.00 | N/A |
| Revenue This Year | $94.10 | N/A |
| Revenue Next Year | $30.33 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.35 | $1.25 |
| 52 Week High | $5.45 | $3.13 |
| Indicator | OABI | PSEC |
|---|---|---|
| Relative Strength Index (RSI) | 42.52 | 26.81 |
| Support Level | $4.53 | N/A |
| Resistance Level | $5.43 | $2.33 |
| Average True Range (ATR) | 0.32 | 0.12 |
| MACD | -0.05 | -0.01 |
| Stochastic Oscillator | 4.76 | 1.22 |
OmniAb Inc licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for its partners' drug development efforts. At the heart of the OmniAb platform is what it calls Biological Intelligence, which powers the immune systems of proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.
Prospect Capital Corp is a financial services company that mainly lends to and invests in middle market privately-held companies. It is a closed-end investment company. Its investment objective is to generate both current income and long-term capital appreciation. It has single operating and reporting segment.